CALL US NOW 0207 939 0780
PLEASE DONATE

HEALTHCARE

Initial Diagnosis Report Launched

Early this year The Haemophilia Society began a project to understand the experiences of families when their child is initially diagnosed with a bleeding disorder. Drawing on some of the stories shared through our #bruisednotabused campaign we reached out to our community to ask them to share their experiences. We

Read More

Take part in our inhibitor survey

We’re conducting a survey among people aged 16+ with a bleeding disorder who have an inhibitor and their family members. An inhibitor is a type of antibody that prevents factor replacement treatment from working. When an inhibitor develops, it binds to factor concentrates such as factor VIII or factor IX,

Read More

UK launches FibCLOT®▼ LFB’s human fibrinogen concentrate

LFB Biopharmaceuticals announced today the UK launch of FibCLOT, its human fibrinogen concentrate. This follows the granting of a UK Marketing Authorisation in April 2016, after a decentralised application to the Regulatory Authorities in Europe, and offers increased therapeutic choices for affected patients. FibCLOT® is indicated for the treatment and perioperative

Read More

Direct-acting Antiviral (DAA) treatment for Hepatitis C risks Hepatitis B reactivation

New guidance from the Medicines and Healthcare products Regulatory Agency (MHRA) advises that all hepatitis C patients should be screened for hepatitis B before starting treatment with new Direct-acting Antivirals (DAAs). If patients are infected with both viruses this does not preclude treatment but this should be monitored and managed.

Read More